Assay Development and Screening
Fraunhofer Institute for Molecular Biology and Applied Ecology ScreeningPort Fraunhofer-IME SP
Hamburg, Germany
http://screeningport.com/about-us/team
Sheraz Gul is currently in the Assay Development and Screening department of the Fraunhofer-IME SP where he focuses on small molecule drug discovery across many disease areas. He manages a group that is responsible for developing assays that are subsequently utilized in High Throughput Screening campaigns, as well as validation of Hit compounds and this includes determining their mechanism of action. Prior to this, he worked for GlaxoSmithKline for 7 years where he developed biochemical and cellular assays for High Throughput Screening as well and Hit compound characterization. He has a PhD and 5 years post-doctoral research experience all from the University of London. He has co-authored numerous papers, book chapters and the Enzyme Assays: Essential Data Handbook. In addition, he has been appointed to the editorial board of the European Pharmaceutical Review. Sheraz Gul has experience in progressing small molecule drug discovery programs from the target identification stage through to Lead compound selection. His contributions to these activities have led to multiple publications in peer-reviewed journals, talks at scientific conferences, the identification of multiple Lead series and two development Candidates. Currently, he is also work-package lead in the EU-FP7 projects that focus on neglected parasitic diseases (NMTrypI and PDE4NPD).
